In December 2025, Chengdu Maxvax Biotechnology Co., Ltd. (hereinafter referred to as “Maxvax”) announced the completion of a D+ round financing totaling several hundred million RMB. This round was jointly invested by Chengdu Sci-Tech Investment, Shenzhen Capital Group, Guosheng Capital, and Linchuang Blue Bay. The funds raised will be primarily used to support the launch and commercialization of the recombinant herpes zoster (shingles) vaccine, the Phase III clinical trials of the recombinant respiratory syncytial virus (RSV) vaccine, as well as the preclinical development and international cooperation of multiple innovative vaccine pipelines.

Dr. Dexiang Chen, founder of Maxvax, stated:
“We would like to express our sincere gratitude to the Chengdu Future Industry Fund managed by Chengdu Sci-Tech Investment, as well as Shenzhen Capital Group, Guosheng Capital, and Linchuang Blue Bay, for their recognition and support. The company will leverage the funds raised in this round to further increase R&D investment and accelerate the clinical development and commercialization of the herpes zoster vaccine and the RSV vaccine. We strive to achieve commercialization within the next one to two years and contribute to the cause of human health.”

Maxvax will continue to uphold its core values of “Integrity First, Excellence Through Innovation, Boundaryless Collaboration, and Global Service,” and is committed to addressing global public health challenges by providing solutions for the prevention and control of major diseases and infectious illnesses. Leveraging its leading innovative R&D capabilities and rapidly expanding commercial-scale manufacturing capacity, Maxvax has been growing at a high speed. To date, the company has completed its D round of financing, with cumulative funding exceeding RMB 2 billion.

Maxvax focuses on the research, development, production, and commercialization of innovative human and veterinary (including pet) vaccines. Based on internationally leading novel adjuvant technologies, recombinant protein platforms, and immunological evaluation platforms, the company has established a broad pipeline of major innovative vaccine candidates. It possesses nearly 20 adjuvant raw materials, has developed three mature delivery system categories, and more than 10 composite formulations, forming a vertically integrated industrial chain spanning adjuvant raw material R&D and production through to adjuvant formulation development and application.

Maxvax has built a diversified R&D pipeline targeting infectious diseases, allergic diseases, and oncology, including multiple prophylactic vaccines against major infectious diseases, as well as therapeutic vaccines for HPV infection, allergic diseases, and cancer. To advance the industrialization of novel adjuvants and human vaccines, an innovative vaccine technology transfer and scale-up platform has been completed, and construction of an industrialization base has been initiated.